WO2015156439A1 - Composition pour améliorer l'état de la peau, comprenant un extrait d'andrographis paniculata, un andrographolide ou sel correspondant - Google Patents

Composition pour améliorer l'état de la peau, comprenant un extrait d'andrographis paniculata, un andrographolide ou sel correspondant Download PDF

Info

Publication number
WO2015156439A1
WO2015156439A1 PCT/KR2014/003168 KR2014003168W WO2015156439A1 WO 2015156439 A1 WO2015156439 A1 WO 2015156439A1 KR 2014003168 W KR2014003168 W KR 2014003168W WO 2015156439 A1 WO2015156439 A1 WO 2015156439A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
andrographolide
composition
extract
cheonsimyeon
Prior art date
Application number
PCT/KR2014/003168
Other languages
English (en)
Korean (ko)
Inventor
이재호
유지영
정은선
박덕훈
리쯔단
리우광롱
TANGjian
Original Assignee
바이오스펙트럼(주)
무한극 (중국) 유한공사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오스펙트럼(주), 무한극 (중국) 유한공사 filed Critical 바이오스펙트럼(주)
Priority to CN201480000256.0A priority Critical patent/CN105358676B/zh
Publication of WO2015156439A1 publication Critical patent/WO2015156439A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof

Definitions

  • Another object of the invention to provide a composition for improving skin conditions comprising the composition.
  • the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, an isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid amide.
  • Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
  • composition for improving skin condition of the present invention may be provided as a pharmaceutical composition applied directly to the skin.
  • the cheonsimyeon extract was removed through the solvent fraction hexane and chloroform fraction, and the obtained fraction was fractionated three times with saturated butanol to obtain a butanol fraction 24g. Thereafter, the butanol fraction was purified by silica gel column chromatography and high performance liquid chromatography (HPLC), and then 280 mg of andrographolide was obtained by recrystallization. The andrographolide thus obtained was confirmed in its structure and content (99.8% or more) by mass spectrometry, NMR and HPLC.
  • Human adipose derived stem cells were purchased from Invitrogen (Invitrogen, Carlsbad, CA, USA), and 2% MesenPro RS Growth supplement (10 ml) and 1% GlutaMAX (5 ml) were added to MesenPro RS medium at 37 ° C. Incubated at 5% CO 2 conditions.
  • Human epidermal stem cells (EpSCs) isolated from neonatal foreskin were tested by Kim et al. (Cell Mol Life Sci, 2004, 61: 2774-2781). The cells attached to the culture vessel were isolated at the beginning of the culture through the culture vessel. The initially attached cells are cells rich in 6 integrin (CD49f) and 1 integrin (CD29) related to stem cell ability, 37%, 5% in EpiLife culture (Invitrogen, Carlsbad, CA, USA). Incubated in CO 2 conditions.
  • CD49f 6 integrin
  • CD29 1 integrin
  • MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) analysis.
  • MTT analysis is an analysis method based on the conversion of a substrate containing a tetrazolium ring to blue formazan by mitochondrial dehydrogenase. The level of blue formazan was spectroscopically measured and used as an indirect indicator of cell density. Briefly, cells were exposed to MTT (1 mg / ml) for 3 hours at 37 ° C., then the medium was removed and the cells were lysed with dimethyl sulfoxide (DMSO). The presence of blue formazan after complete dissolution was determined spectroscopically by measuring absorbance at wavelength 570 nm.
  • DMSO dimethyl sulfoxide
  • cheonsimyeon extract and andrographolide was found to increase the proliferation of fat-derived stem cells (ADSCs) and epidermal derived stem cells Concentration-dependently increased (see FIGS. 1 and 2).
  • 3D dermal lattice cultured with fibroblasts is a commonly used test method for identifying fibroblast activity and confirming wound healing efficacy (Tse R, Howard J, Wu Y, Gan BS.Enhanced Dupuytren's disease fibroblast populated collagen lattice contraction is independent of endogenous Active TGF-beta2.BMC Musculoskelet Disord. 2004 Nov 12; 5 (1): 41.) increases the extracellular matrix component (ECM) in collagen gels, resulting in gel shrinkage.
  • ECM extracellular matrix component
  • the extract of cheonsimyeon extract and andrographolide was reduced by about 26% and 10% at 30ppm compared to the control, the extract of cheonsimyeon extract and andrographolide increased the contraction of collagen gel. I could see it.
  • positive control TGF- ⁇ 1 Transforming Growth Factor beta-1 also increased the contraction of collagen gel of fibroblasts.
  • Test group 1 Control Purified water 71 71 71 glycerin 8.0 8.0 8.0 Butylene glycol 4.0 4.0 4.0 Cheonsimyeon Extract 0.1 0 0 Andrographolide 0 0.1 0 Caprylic Capri Triglyceride 8.0 8.0 8.0 Squalane 5.0 5.0 5.0 Cetearyl Glucoside 1.5 1.5 1.5 Sorbitan stearate 0.4 0.4 0.4 Cetearyl Alcohol 1.0 1.0 1.0 1.0 Trimethanolamine 0.1 0.1 0.1 Gross weight 100 100 100 100 100 100
  • the skin external preparation prepared by the method of 6-1 above was applied to the upper forearm area for a total of nine 24-hour cumulative patch every other day for 30 healthy adults to determine whether Cheonsimyeon extract or andrographolide irritated the skin. Whether or not was measured.
  • a skin external preparation containing cheonsimyeon extract and andrographolide was used as a squalane base.
  • Average responsiveness [[response index ⁇ responsiveness / total number of subjects ⁇ highest score (4 points)] ⁇ 100] / number of tests
  • ⁇ 1 point, + 2 points and + + 4 points in the reactivity it is determined as a safe composition when the average reactivity is less than 3.
  • a nutritious lotion containing cheonsimyeon extract or andrographolide as an active ingredient was prepared according to a conventional method.
  • a tablet comprising a cheonsimyeon extract or andrographolide as an active ingredient
  • the tablets were prepared by mixing the components shown in Table 10 and then tableting according to the manufacturing method of conventional tablets.
  • the capsules were prepared by mixing the components shown in Table 11 and then filling into gelatin capsules according to the conventional method for preparing capsules.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne : une composition pour l'augmentation du caractère souche ou de la prolifération de cellules de la peau, la composition comprenant au moins l'un parmi un extrait d'Andrographis paniculata, un andrographolide ou un sel correspondant ; et une composition pour améliorer l'état de la peau, comprenant la composition. La composition de la présente invention induit la sécrétion d'un facteur de croissance à partir de cellules souches et de cellules de la peau et favorise la prolifération cellulaire. De plus, la composition de la présente invention induit l'amélioration de l'état de la peau, tel que l'amélioration des rides de la peau, l'inhibition du vieillissement de la peau, l'amélioration de l'élasticité de la peau, la régénération de la peau ou l'amélioration de lésions ou de cicatrices formées sur l'épiderme, etc.
PCT/KR2014/003168 2014-04-08 2014-04-14 Composition pour améliorer l'état de la peau, comprenant un extrait d'andrographis paniculata, un andrographolide ou sel correspondant WO2015156439A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201480000256.0A CN105358676B (zh) 2014-04-08 2014-04-14 含穿心莲萃取物或穿心莲内酯或其盐的皮肤状态改善用合成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2014-0041820 2014-04-08
KR1020140041820A KR101694958B1 (ko) 2014-04-08 2014-04-08 천심련추출물 또는 안드로그라폴라이드 또는 이의 염을 포함하는 피부상태 개선용 조성물

Publications (1)

Publication Number Publication Date
WO2015156439A1 true WO2015156439A1 (fr) 2015-10-15

Family

ID=54288006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2014/003168 WO2015156439A1 (fr) 2014-04-08 2014-04-14 Composition pour améliorer l'état de la peau, comprenant un extrait d'andrographis paniculata, un andrographolide ou sel correspondant

Country Status (3)

Country Link
KR (1) KR101694958B1 (fr)
CN (1) CN105358676B (fr)
WO (1) WO2015156439A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114507198A (zh) * 2022-04-02 2022-05-17 江西成必信生物科技有限公司 一种穿心莲内酯提取工艺

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101843065B1 (ko) * 2016-01-06 2018-03-28 바이오스펙트럼 주식회사 카노신, 대두 펩타이드 및 천심련 추출물을 포함하는 항노화용 조성물
CN108379094B (zh) * 2018-04-24 2021-09-14 广州暨南大学医药生物技术研究开发中心有限公司 包含生物活性美容多肽脂质立方晶的组合物及其在化妆品中的应用
CN109010108A (zh) * 2018-08-31 2018-12-18 广州中医药大学(广州中医药研究院) 亚硫酸氢钠穿心莲内酯抗皮肤光老化的应用及防晒霜
KR102308756B1 (ko) * 2020-08-27 2021-10-06 주식회사 코리아나화장품 귤껍질 및 칼메그의 혼합추출물을 유효성분으로 함유하는 화장료 조성물
CA3221157A1 (fr) * 2021-06-04 2022-12-08 Seon Ju Lee Composition cosmetique anti-vieillissement
KR102555418B1 (ko) * 2021-08-30 2023-07-17 주식회사 코리아나화장품 바실러스 서브틸리스 j2k-351 균주를 이용하여 발효된 천심련 및 바위손의 혼합추출물을 유효 성분으로 함유하는 피부보호용 화장료 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1029927A (ja) * 1996-07-12 1998-02-03 Shiseido Co Ltd 抗老化剤
KR20050067951A (ko) * 2003-12-29 2005-07-05 주식회사 엘지생활건강 안드로그라폴라이드 또는 안드로그라폴라이드를유효성분으로 함유하는 천심련 추출물을 포함하는가려움증 억제 또는 완화 조성물
KR20090131767A (ko) * 2008-06-19 2009-12-30 주식회사 엘지생활건강 피부미백 화장료 조성물
US20110077295A1 (en) * 2007-08-08 2011-03-31 Panorama Research Inc. Andrographolide derivatives and use thereof in manufacture of medicaments

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926720B1 (fr) * 2008-01-24 2011-09-09 Jean Noel Thorel Composition cosmetique destinee a bloquer la pigmentation de la peau induite par les rayonnements uv
JP2013209299A (ja) * 2012-03-30 2013-10-10 Kose Corp Ｄｎａ損傷抑制剤並びにこれを含有する皮膚外用剤、化粧料および飲食物
CN102716338A (zh) * 2012-06-29 2012-10-10 遵义臻坤中草医药研究所 一种激活人体休眠干细胞、延缓衰老的中药组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1029927A (ja) * 1996-07-12 1998-02-03 Shiseido Co Ltd 抗老化剤
KR20050067951A (ko) * 2003-12-29 2005-07-05 주식회사 엘지생활건강 안드로그라폴라이드 또는 안드로그라폴라이드를유효성분으로 함유하는 천심련 추출물을 포함하는가려움증 억제 또는 완화 조성물
US20110077295A1 (en) * 2007-08-08 2011-03-31 Panorama Research Inc. Andrographolide derivatives and use thereof in manufacture of medicaments
KR20090131767A (ko) * 2008-06-19 2009-12-30 주식회사 엘지생활건강 피부미백 화장료 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AL-BAYATY, F. H. ET AL.: "Effect of Andrographis paniculata leaf extract on wound healing in rats", NATURAL PRODUCT RESEARCH, vol. 26, no. 5, 9 June 2011 (2011-06-09), pages 423 - 429 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114507198A (zh) * 2022-04-02 2022-05-17 江西成必信生物科技有限公司 一种穿心莲内酯提取工艺

Also Published As

Publication number Publication date
CN105358676A (zh) 2016-02-24
KR20150116659A (ko) 2015-10-16
KR101694958B1 (ko) 2017-01-10
CN105358676B (zh) 2021-08-10

Similar Documents

Publication Publication Date Title
WO2015156439A1 (fr) Composition pour améliorer l'état de la peau, comprenant un extrait d'andrographis paniculata, un andrographolide ou sel correspondant
WO2019045259A2 (fr) Composition cosmétique comprenant un extrait de fleur de dendrobium candidum wallich ex lindley
WO2015002393A1 (fr) Composition de traitement ou de prévention d'une maladie cutanée inflammatoire comprenant, comme ingrédient actif, un extrait d'agrumes immatures ou de la synéphrine, ou leur sel
WO2011059292A2 (fr) Concentré ou extrait de pousse d'aloès officinal favorisant fortement la croissance des cellules cutanées et présentant des effets anti-allergiques et antioxydants supérieurs
WO2016159567A2 (fr) Composition pour favoriser la croissance capillaire ou la régénération capillaire, et à effet anti-inflammatoire
WO2013129723A1 (fr) Composition d'amélioration d'états de la peau comprenant de l'hordénine
WO2022260454A1 (fr) Composition pour le traitement de la dermatite atopique ou le renforcement de la barrière cutanée ou la prévention du vieillissement de la peau, comprenant un extrait de forsythia velutina nakai
KR20220142990A (ko) 택란 추출물을 유효성분으로 함유하는 피부미백용 조성물
WO2020071630A1 (fr) Composition pour améliorer la peau comprenant des extraits de produits naturels
WO2017200288A1 (fr) Composition pour le blanchiment de la peau, la prévention du vieillissement de la peau ou l'amélioration des rides de la peau, comprenant un extrait médicinal oriental naturel en tant que substance active
WO2017213346A1 (fr) Composition contenant de la diosmine ou son sel comme ingrédient actif et présentant un effet d'amélioration de l'hydratation de la peau, d'exfoliation de la peau, de renforcement de l'élasticité de la peau, d'inhibition de l'érythème, de réduction des rides de la peau, ou de retardement du photovieillissement de la peau
WO2018111042A2 (fr) Composition cosmétique comprenant un extrait de plantes médicinales en tant qu'ingrédient actif
WO2020256464A1 (fr) Utilisation d'une fraction d'extrait de tubercule d'apios americana ayant une activité anti-inflammatoire comme agent préventif ou thérapeutique de la gastrite alcoolique, et son procédé de production
WO2017119535A1 (fr) Composition anti-âge comprenant de la carnosine, peptide de soja, et extrait d'andrographis paniculata
WO2014119826A1 (fr) Composition cosmétique pour le blanchiment ou l'atténuation de rides comprenant un extrait d'algue en tant que principe actif
WO2019139403A1 (fr) Composition contenant de la séricine, un extrait de torilis japonica et un extrait de viscum album pour la régénération de la peau, l'apaisement de la peau ou la cicatrisation des plaies
WO2014003224A1 (fr) Compositions de blanchiment de la peau comprenant de la madécassoside
WO2021215882A1 (fr) Composition pour prévenir la chute des cheveux ou favoriser la pousse des cheveux comprenant un extrait de péricarpe de camélia en tant que principe actif
WO2018151563A1 (fr) Composition pour prévenir le photovieillissement et soulager les rides de la peau, contenant un extrait de cosmos bipinnatus
WO2017142368A2 (fr) Composition permettant de prévenir et de traiter une maladie cutanée allergique ou inflammatoire
WO2014157910A1 (fr) Composition contenant un extrait de thanaka traité par une enzyme
WO2020246766A1 (fr) Composition pour prévenir ou atténuer le vieillissement cutané, contenant un extrait de rhodiola sachalinensis fermenté à l'aide de bovista plumbea
WO2016122091A1 (fr) Composition pharmaceutique pour la prévention et le traitement de maladie allergique ou de dermatite de contact, comprenant un extrait de cymbidium comme principe actif
WO2021002642A1 (fr) Composition pour prévenir ou traiter la polyarthrite rhumatoïde, comprenant du venin de serpent
WO2012173383A2 (fr) Composition à usage externe pour l'épiderme, contenant en tant que principe actif du cryptotanshinone

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480000256.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14888687

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 26/01/2017)

122 Ep: pct application non-entry in european phase

Ref document number: 14888687

Country of ref document: EP

Kind code of ref document: A1